James Januzzi, MD, and Bonnie Ky, MD, MSCE discuss the discovery of novel biomarkers of cancer therapy-related cardiotoxicity. Moderated by Nicholas Wilcox, MD, MHS.
Sumanta Pal, MD, discusses the treatment of patients with metastatic renal cell carcinoma (mRCC), management of cardiovascular toxicities associated with therapies for mRCC, and the future treatment landscape of mRCC. Moderated by Sarah Waliany, MD, MS.
Commentary by Drs. Pratik Doshi and Martha Gulati discussing how we can improve diversity, equity, and inclusion efforts across cardiology.
Commentary by Dr. Emile Daoud
Commentary by Social Media Editor Anju Bhardwaj
Commentary by Dr. Emile Daoud
Commentary by Dr. Mary Norine Walsh
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides and Dr. Florian Rader
Commentary by Dr. Candice Silversides